BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 12357093)

  • 1. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["Rather overweight and mentally present...". Patients evaluate clozapine].
    Boitz K; Angermeyer MC; Löffler W; Müller P; Priebe S
    Psychiatr Prax; 1999 Jul; 26(4):188-93. PubMed ID: 10457971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
    Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug compliance and health locus of control in schizophrenia].
    Combes C; Feral F
    Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach.
    Santone G; Rucci P; Muratori ML; Monaci A; Ciarafoni C; Borsetti G
    Psychiatry Res; 2008 Apr; 158(3):324-34. PubMed ID: 18262656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognosis of schizophrenia from the viewpoint of patients and relatives. An explorative study].
    Holzinger A; Müller P; Priebe S; Angermeyer MC
    Psychiatr Prax; 2002 Apr; 29(3):154-9. PubMed ID: 11961717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the schizophrenic patients' level of information about their disease and their treatment?
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000 Oct; 26 Spec No 1():15-22. PubMed ID: 11294058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relapse in schizophrenia: an exploratory study of the joint conceptions of patients, parents and caregivers].
    Koenig M; Castillo MC; Urdapilleta I; Le Borgne P; Bouleau JH
    Encephale; 2011 Jun; 37(3):207-16. PubMed ID: 21703436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.